ArticleChinese journal of integrative medicine2026
Qingxin Jieyu Granule Ameliorates Myocardial Ischemia/Reperfusion Injury by Inhibiting Cardiomyocyte Pyroptosis via Regulating Circulating Exosomes.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the protective effect of Qingxin Jieyu Granule (QXJYG) on myocardial ischemia/reperfusion (I/R) injury by inhibiting cardiomyocyte pyroptosis via circulating exosomes.
methodsSeventy-five Wistar rats were randomly assigned to 5 groups using a random number table (15 rats per group): sham-operated, model, low-, medium-, and high-dose QXJYG groups (L-QXJYG, M-QXJYG, and H-QXJYG). The L-QXJYG, M-QXJYG, and H-QXJYG groups were administered QXJYG at doses of 2.87, 5.73, and 11.46 g/kg, respectively, twice daily via intragastric administration for 28 consecutive days. The model group received an equal volume of normal saline following the same schedule. Following 28 days of administration, myocardial I/R injury was induced 1 h after the final dose. Myocardial infarction size, histopathological changes, and expression of key pyroptosis-related molecules in cardiac tissue were assessed. An oxygen-glucose deprivation/reperfusion model using H9c2 cardiomyocytes was established to investigate the cardioprotective mechanism of QXJYG, emphasizing the role of circulating exosomes in modulating pyroptosis through evaluations of cell viability, pyroptotic morphology, and associated molecular expression.
resultsIn vivo experiments demonstrated that QXJYG significantly reduced myocardial infarction size, improved histopathological morphology, suppressed the inflammatory response, and inhibited myocardial pyroptosis (all P<0.05). In vitro, QXJYG was shown to enhance H9c2 cardiomyocyte viability, attenuate inflammation, and suppress pyroptosis by inhibiting the NLRP3/Caspase-1/GSDMD pathway via circulating exosomes (all P<0.05).
conclusionQXJYG alleviates myocardial I/R injury by inhibiting cardiomyocyte pyroptosis through circulating exosomes, potentially via modulation of the NLRP3/ Caspase-1/GSDMD pathway.
Indexed as
Identifiers
41820724What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.